Výsledky vyhledávání

Akademický článek

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM

Publikováno v: OncoImmunology, Vol 7, Iss 8 (2018)

The use of inhibitory checkpoint blockade in the management of glioblastoma has been studied in both preclinical and clinical settings. TIGIT is a novel checkpoint inhibitor recently discovered to play a role in cancer immunity. In this study, we sou

Externí odkaz: https://doaj.org/article/5c158c786ed24843bf3f702d74cfb42f

Zobrazit plný text záznamu

Akademický článek

Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 4, Iss 1 (2016)

Background Glioblastoma (GBM) is a poorly immunogenic neoplasm treated with focused radiation. Immunotherapy has demonstrated synergistic survival effects with stereotactic radiosurgery (SRS) in murine GBM. GITR is a co-stimulatory molecule expressed

Externí odkaz: https://doaj.org/article/1cefcf3139484613b7146d212fd0b0e7

Zobrazit plný text záznamu

Akademický článek

A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection.

Autor: David Gardiner, Jay Lalezari, Eric Lawitz, Michael DiMicco, Rheem Ghalib, K Rajender Reddy, Kyong-Mi Chang, Mark Sulkowski, Steven O' Marro, Jeffrey Anderson, Bing He, Vikram Kansra, Fiona McPhee, Megan Wind-Rotolo, Dennis Grasela, Mark Selby, Alan J Korman, Israel Lowy

Publikováno v: PLoS ONE, Vol 8, Iss 5, p e63818 (2013)

Expression of the programmed death 1 (PD-1) receptor and its ligands are implicated in the T cell exhaustion phenotype which contributes to the persistence of several chronic viral infections, including human hepatitis C virus (HCV). The antiviral po

Externí odkaz: https://doaj.org/article/5889a97179954738bd4d816026b9389b

Zobrazit plný text záznamu

Commercialization of Ceres SteelCell® Technology for Power Generation and Electrolysis

Autor: Robert Leah, Adam Bone, Per Hjalmarsson, Ahmet Selcuk, Mike Lankin, Mahfujur Rahman, Florence Felix, Jeffrey De Vero, Chandra Macauley, Cecile Charbonneau, Laura Rios, Subhasish Mukerjee, Caroline Hargrove, Mark Selby

Publikováno v: ECS Transactions. 111:121-131

Ceres’ SteelCell® technology is establishing itself as the global standard for SOC. The technology is rapidly moving to volume production, with Robert Bosch GmbH in Germany and Doosan Fuel Cell in South Korea having licenses to manufacture Ceres S

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::223ff141fc8fd439188dc1c9c3aa3310
https://doi.org/10.1149/11106.0121ecst

Zobrazit plný text záznamu

Current Status of Ceres Electrolysis Programme

Autor: Per Hjalmarsson, Jonathan Harman, Chandra Macauley, Ian Methley, Joshua Ryley, Amin Zerfa, Caroline Hargrove, Mark Selby

Publikováno v: ECS Transactions. 111:977-989

This paper reports on experimental testing and verification of Ceres solid oxide technology in electrolysis mode at all levels from small single cells to a 100-kW module. This programme has demonstrated that the electrochemical performance of Ceres c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::82fc8d133feca02071469d7a377fc07a
https://doi.org/10.1149/11106.0977ecst

Zobrazit plný text záznamu

Preclinical Characterization of Relatlimab, a Human LAG-3–Blocking Antibody, Alone or in Combination with Nivolumab

Autor: Kent Thudium, Mark Selby, Julie A. Zorn, Gregory Rak, Xi-Tao Wang, Roderick Todd Bunch, Jason M. Hogan, Pavel Strop, Alan J. Korman

Publikováno v: Cancer Immunology Research. 10:1175-1189

Novel therapeutic approaches combining immune checkpoint inhibitors are needed to improve clinical outcomes for patients with cancer. Lymphocyte-activation gene 3 (LAG-3) is an immune checkpoint molecule that inhibits T-cell activity and antitumor im

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::998abd82ce6e0d18fac052d7e8514843
https://doi.org/10.1158/2326-6066.cir-22-0057

Zobrazit plný text záznamu

Data from Preclinical Characterization of Relatlimab, a Human LAG-3–Blocking Antibody, Alone or in Combination with Nivolumab

Autor: Alan J. Korman, Pavel Strop, Jason M. Hogan, Roderick Todd Bunch, Xi-Tao Wang, Gregory Rak, Julie A. Zorn, Mark Selby, Kent Thudium

Novel therapeutic approaches combining immune-checkpoint inhibitors are needed to improve clinical outcomes for patients with cancer. Lymphocyte-activation gene 3 (LAG-3) is an immune-checkpoint molecule that inhibits T-cell activity and antitumor im

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61f873646c4378fa6cbb3fc2c62d7017
https://doi.org/10.1158/2326-6066.c.6551000.v1

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání